Skip to main content

Advertisement

SpringerLink
Log in

Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with 131I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC).

Materials and methods

A total of 47 patients (13 men, 34 women; age 54.2 ± 13.6 years) with radioiodine-refractory PTC underwent therapy consisting of consecutive treatment with 131I and RA. Each 131I/RA treatment cycle involved the administration of oral isotretinoin for 6 weeks at 1–1.5 mg/kg daily followed by a single oral dose of 131I (range 5.5-16.7 GBq). Therapeutic responses were determined using serum thyroglobulin (Tg) levels and the change in tumour size 6 months after completing the 131I/RA therapy. Biological parameters and pathological parameters before and after combined therapy were compared.

Results

After completing 131I/RA therapy, 1 patient showed a complete response, 9 partial response, 9 stable disease, and 28 progressive disease, representing an overall response rate of 21.3%. Univariate analysis revealed that an age of <45 years and a persistently high serum Tg level were related to a good response. No clinical response was achieved when metastases showing no iodine uptake were present. Multivariate regression analysis showed that an age of <45 years was significantly associated with a good response. Of the 24 patients with well-differentiated carcinoma, 5 (20.8%) responded to 131I/RA therapy, whereas all 6 patients with poorly differentiated carcinoma failed to respond.

Conclusion

131I/RA therapy was found to elicit a response rate of 21.3% among patients with radioiodine-refractory PTC, and an age of <45 years was found to be significantly associated with a good response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Reference

  1. Goretzki PE, Simon D, Frilling A, et al. Surgical intervention for differentiated thyroid carcinoma. Br J Surg. 1994;80:1009–12.

    Article  Google Scholar 

  2. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–57.

    Article  PubMed  CAS  Google Scholar 

  3. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4–14.

    Article  CAS  Google Scholar 

  4. Hansen LA, Sigman CC, Andreola F, Rose SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271–9.

    Article  PubMed  CAS  Google Scholar 

  5. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–93.

    Article  PubMed  CAS  Google Scholar 

  6. Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2001;14:153–74.

    Article  PubMed  CAS  Google Scholar 

  7. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997;240:832–8.

    Article  PubMed  CAS  Google Scholar 

  8. Lee YJ, Chung JK, Shin JH, Kang JH, Jeong JM, Lee DS. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid. 2004;14:889–95.

    Article  PubMed  Google Scholar 

  9. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab. 1999;84:2249–57.

    Article  Google Scholar 

  10. Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metabol. 2000;85:2889–96.

    Article  CAS  Google Scholar 

  11. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998;22:569–74.

    Article  PubMed  CAS  Google Scholar 

  12. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–19.

    PubMed  Google Scholar 

  13. Grünwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555–8.

    PubMed  Google Scholar 

  14. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;240:832–8.

    Google Scholar 

  15. Fernández CA, Puig-Domingo M, Lomeña F, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009;32:228–33.

    PubMed  Google Scholar 

  16. Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer – final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–82.

    Article  PubMed  CAS  Google Scholar 

  17. Grünig T, Tiepolt C, Zoephel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer – does it hold its promise? Eur J Nucl Med Mol Imaging. 2003;148:395–402.

    Google Scholar 

  18. Courbon F, Zerdoud S, Bastie D, et al. Defective efficacy of retinoid acid treatment in patients with metastatic thyroid carcinoma. Thyroid. 2006;16:1025–31.

    Article  PubMed  CAS  Google Scholar 

  19. Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727–34.

    Article  PubMed  Google Scholar 

  20. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191–5.

    PubMed  CAS  Google Scholar 

  21. Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002;57:215–21.

    Article  Google Scholar 

  22. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74:983–6.

    PubMed  CAS  Google Scholar 

  23. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. World Health Organization: International histological classification of tumours. 2nd ed. Berlin: Springer Verlag; 1988.

    Google Scholar 

  24. Ahn HY, Park YJ. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med. 2009;77:537–42.

    Google Scholar 

  25. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4701–4.

    Article  Google Scholar 

  26. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.

    Article  PubMed  CAS  Google Scholar 

  27. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1:162–9.

    Article  PubMed  CAS  Google Scholar 

  28. Teixeira C, Pratt MA. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol. 1997;11:1191–202.

    Article  PubMed  CAS  Google Scholar 

  29. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ. 1998;1998:11–9.

    Article  Google Scholar 

  30. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16:453–61.

    Article  PubMed  CAS  Google Scholar 

  31. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehang-Ro, Jongno-Gu, Seoul, 110–744, Republic of Korea

    So Won Oh, Seung-hwan Moon, Dong Soo Lee & June-Key Chung

  2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    Do Joon Park & Bo Youn Cho

  3. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea

    Kyeong Cheon Jung

  4. Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    So Won Oh

  5. Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University WCU Graduate School of Convergence Science and Technology, Seoul, Republic of Korea

    Dong Soo Lee

Authors
  1. So Won Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seung-hwan Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Do Joon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Youn Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyeong Cheon Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to June-Key Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oh, S.W., Moon, Sh., Park, D.J. et al. Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging 38, 1798–1805 (2011). https://doi.org/10.1007/s00259-011-1849-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1849-2

Keywords

Search

Navigation